Our results identify S100A8/A9 as a potential marker of cardiac dysfunction in sepsis patients and promote systemic S100A8/A9 blockade as a viable treatment to ameliorate SIMD and improve patient prognosis. The gene discussed is S100A8; the disease is Sepsis.